The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 302-309.e11

  Scott, Frank I ^a,b   Vajravelu, Ravy K ^a   Bewtra, Meenakshi ^a,b   Mamtani, Ronac ^a,b   Lee, Dale ^b,c   Goldberg, David S ^a,b   Lewis, James D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Azathioprine; Crohn's disease; Infliximab; Lymphoma

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; AGE SPECIFIC CARE; AGED; ARTICLE; CASE REPORT; CROHN DISEASE; HAZARD RATIO; HUMAN; INFECTION RISK; LIFE EXPECTANCY; LYMPHOMA; MALE; MONOTHERAPY; PERSONALIZED MEDICINE; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; T CELL LYMPHOMA; ADVERSE EFFECTS; COMMUNICABLE DISEASES; DRUG COMBINATION; FEMALE; MIDDLE AGED; RISK ASSESSMENT; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; AZATHIOPRINE; COMMUNICABLE DISEASES; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; LYMPHOMA; MALE; MIDDLE AGED; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT;

EID: 84927140878     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.058     Document Type: Article

References (33)

1. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEngl J Med 2010, 362:1383-1395.
2. Lemann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
3. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
4. Terdiman J.P., Gruss C.B., Heidelbaugh J.J., et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013, 145:1459-1463.
5. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306:2331-2339.
6. Long M.D., Martin C., Sandler R.S., et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 2013, 108:240-248.
7. Herrinton L.J., Liu L., Weng X., et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011, 106:2146-2153.
8. Beaugerie L., Brousse N., Bouvier A.M., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
9. Long M.D., Herfarth H.H., Pipkin C.A., et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8:268-274.
10. Herrinton L.J., Liu L., Abramson O., et al. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf 2012, 21:49-52.
11. Belhadj K., Reyes F., Farcet J.P., et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003, 102:4261-4269.
12. Masoomi H., Kang C.Y., Chaudhry O., et al. Predictive factors of early bowel obstruction in colon and rectal surgery: data from the Nationwide Inpatient Sample, 2006-2008. JAm Coll Surg 2012, 214:831-837.
13. Cottone M., Kohn A., Daperno M., et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:30-35.
14. Lewis J.D., Schwartz J.S., Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118:1018-1024.
15. Lewis J.D., Gelfand J.M., Troxel A.B., et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008, 103:1428-1435.
16. Arias E. National vital statistics reports. United States Life Tables, 2007 2011;59:1-61.
17. Howlader N, Noone A, Krapcho M, etal. SEER cancer statistics review, 1975-2010. Available at: . Accessed April 2013. http://seer.cancer.gov/csr/1975_2010/.
18. Gregor J., McDonald J., Klar N., et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997, 3:265-276.
19. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
20. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
21. Kopylov U., Al-Taweel T., Yaghoobi M., et al. Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: a meta-analysis. JCrohn's Colitis 2014, 8:S50-S51.
22. Jones J., Kaplan G.G., Peyrin-Biroulet L., et al. Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data. Gastroenterology 2013, 144:S179.
23. Lichtenstein G.R., Cohen R.D., Feagan B.G., et al. Safety of infliximab and other Crohn's disease therapies: Treat™ registry data with a mean of 5 years of follow-up. Gastroenterology 2011, 140:S773.
24. Olin R.L., Kanetsky P.A., Ten Have T.R., et al. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol 2010, 85:255-260.
25. Briggs A.H., Claxton K., Sculpher M.J. Decision modelling forhealth economic evaluation: Oxford handbooks in health economic evaluation 2006, 77-120. Oxford University Press, Oxford.
26. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. Gut 2012, 61:476-483.
27. Lin Z., Bai Y., Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives forCrohn's disease. Eur J Gastroenterol Hepatol 2011, 23:1100-1110.
28. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
29. Pariente B., Pineton de Chambrun G., Krzysiek R., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:1199-1206.
30. Khan N., Abbas A.M., Lichtenstein G.R., et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013, 145:1007-1015.
31. Feagan B.G., McDonald J.W.D., Panaccione R., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014, 146:681-688.
32. Long M.D., Martin C.F., Pipkin C.A., et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012, 143:390-399.e1.
33. Osterman M.T., Sandborn W.J., Colombel J-F., et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014, 146:941-949.